Selected research
Industry Research
Herceptin (Trastuzumab) Industry Research Report 2026
Market perspective
The global Herceptin (Trastuzumab) market was valued at US$ million in 2025 and is projected to reach US$ million by 2032, implying a CAGR of % over 2026–2032.
The North America market for Herceptin (Trastuzumab) is projected to increase from US$ million in 2026 to US$ million by 2032, corresponding to a CAGR of % over 2026–2032.
The Europe market for Herceptin (Trastuzumab) is projected to rise from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026–2032.
Read the full market overview
The Asia Pacific market for Herceptin (Trastuzumab) is expected to grow from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026–2032.
Leading global manufacturers of Herceptin (Trastuzumab) include Teva Pharmaceutical, Novartis AG, Merck, Mylan, Pfizer, Amgen, Samsung Bioepis, Roche Diagnostics and Mundipharma, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.
Report Scope
This report quantifies the global Herceptin (Trastuzumab) market in terms of revenue (US$ million) and, where applicable, sales volume (K Units), using 2025 as the base year and providing annual historical and forecast data for 2021–2032.
It standardizes definitions of Types and Applications, harmonizes vendor attribution, and presents comparable time series by company, Type, Application, and region/country, including indicative price bands (US$/K Units) and concentration ratios (CR5/CR10).
The outputs are intended to support strategy development, budgeting, and performance benchmarking for brand owners, manufacturers, retailers, channel partners, and investors; data are structured with consistent units and fields to facilitate integration into internal FP&A and BI systems.
Key Companies & Market Share Insights
This section profiles leading manufacturers, combining 2021–2025 results with a 2026–2032 outlook. It reports revenue, market share, price bands, product and application mix, regional and channel mix, and key developments (M&A, capacity additions, certifications). It also provides global revenue, average price, and—where applicable—sales volume by manufacturer, and calculates CR5/CR10 and rank changes to support comparative benchmarking.
Herceptin (Trastuzumab) Market by Company
Teva Pharmaceutical
Novartis AG
Merck
Mylan
Pfizer
Amgen
Samsung Bioepis
Roche Diagnostics
Mundipharma
Mabion
InvivoGen
Genentech
Celltrion
Bio-Techne
Biocon Limited
AryoGen Biopharma
Abnova Corporation
Herceptin (Trastuzumab) Segment by Type
Breast Cancer
Stomach Cancer
Others
Herceptin (Trastuzumab) Segment by Application
Hospital
Medical Center
Herceptin (Trastuzumab) Segment by Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Netherlands
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Southeast Asia
South America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
Key Drivers & Barriers
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Herceptin (Trastuzumab) market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Herceptin (Trastuzumab) and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Herceptin (Trastuzumab).
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Research objectives, research methods, data sources, data cross-validation;
Chapter 2: Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc.), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 3: Detailed analysis of Herceptin (Trastuzumab) manufacturers competitive landscape, price, production and value market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product production/output, value, price, gross margin, product introduction, recent development, etc.
Chapter 5: Production/output, value of Herceptin (Trastuzumab) by region/country. It provides a quantitative analysis of the market size and development potential of each region in the next six years.
Chapter 6: Consumption of Herceptin (Trastuzumab) in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and production of each country in the world.
Chapter 7: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 8: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 10: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 11: The main points and conclusions of the report.
More report detail
Tables and figures
Scope & coverage.
Types
- Breast Cancer
- Stomach Cancer
- Others
Applications
- Hospital
- Medical Center
Companies covered
- Teva Pharmaceutical
- Novartis AG
- Merck
- Mylan
- Pfizer
- Amgen
- Samsung Bioepis
- Roche Diagnostics
- Mundipharma
- Mabion
- InvivoGen
- Genentech
- Celltrion
- Bio-Techne
- Biocon Limited
- AryoGen Biopharma
- Abnova Corporation
Inside the report.
1 Preface
- 1.1 Scope of Report
- 1.2 Reasons for Doing This Study
- 1.3 Research Methodology
- 1.4 Research Process
- 1.5 Data Source
- 1.5.1 Secondary Sources
- 1.5.2 Primary Sources
2 Market Overview
- 2.1 Product Definition
- 2.2 Global Market Growth Prospects
- 2.2.1 Global Herceptin (Trastuzumab) Market Size (2021-2032)
- 2.2.2 Global Herceptin (Trastuzumab) Sales (2021-2032)
- 2.2.3 Global Herceptin (Trastuzumab) Market Average Price (2021-2032)
- 2.3 Herceptin (Trastuzumab) by Type
- 2.3.1 Market Value Comparison by Type (2021 VS 2025 VS 2032) & (US$ Million)
- 2.3.2 Breast Cancer
- 2.3.3 Stomach Cancer
- 2.3.4 Others
- 2.4 Herceptin (Trastuzumab) by Application
- 2.4.1 Market Value Comparison by Application (2021 VS 2025 VS 2032)
- 2.4.2 Hospital
- 2.4.3 Medical Center
3 Market Competitive Landscape by Manufacturers
- 3.1 Global Herceptin (Trastuzumab) Market Competitive Situation by Manufacturers (2021 Versus 2025)
- 3.2 Global Herceptin (Trastuzumab) Sales (K Units) of Manufacturers (2021-2026)
- 3.3 Global Herceptin (Trastuzumab) Revenue of Manufacturers (2021-2026)
- 3.4 Global Herceptin (Trastuzumab) Average Price by Manufacturers (2021-2026)
- 3.5 Global Herceptin (Trastuzumab) Industry Ranking, 2024 VS 2025 VS 2026
- 3.6 Global Manufacturers of Herceptin (Trastuzumab), Manufacturing Sites & Headquarters
- 3.7 Global Manufacturers of Herceptin (Trastuzumab), Product Type & Application
- 3.8 Global Manufacturers of Herceptin (Trastuzumab), Established Date
- 3.9 Global Herceptin (Trastuzumab) Market CR5 and HHI
- 3.10 Global Manufacturers Mergers & Acquisition
4 Manufacturers Profiled
- 4.1 Teva Pharmaceutical
- 4.1.1 Teva Pharmaceutical Company Information
- 4.1.2 Teva Pharmaceutical Business Overview
- 4.1.3 Teva Pharmaceutical Herceptin (Trastuzumab) Sales, Revenue and Gross Margin (2021-2026)
- 4.1.4 Teva Pharmaceutical Herceptin (Trastuzumab) Product Portfolio
- 4.1.5 Teva Pharmaceutical Recent Developments
- 4.2 Novartis AG
- 4.2.1 Novartis AG Company Information
- 4.2.2 Novartis AG Business Overview
- 4.2.3 Novartis AG Herceptin (Trastuzumab) Sales, Revenue and Gross Margin (2021-2026)
- 4.2.4 Novartis AG Herceptin (Trastuzumab) Product Portfolio
- 4.2.5 Novartis AG Recent Developments
- 4.3 Merck
- 4.3.1 Merck Company Information
- 4.3.2 Merck Business Overview
- 4.3.3 Merck Herceptin (Trastuzumab) Sales, Revenue and Gross Margin (2021-2026)
- 4.3.4 Merck Herceptin (Trastuzumab) Product Portfolio
- 4.3.5 Merck Recent Developments
- 4.4 Mylan
- 4.4.1 Mylan Company Information
- 4.4.2 Mylan Business Overview
- 4.4.3 Mylan Herceptin (Trastuzumab) Sales, Revenue and Gross Margin (2021-2026)
- 4.4.4 Mylan Herceptin (Trastuzumab) Product Portfolio
- 4.4.5 Mylan Recent Developments
- 4.5 Pfizer
- 4.5.1 Pfizer Company Information
- 4.5.2 Pfizer Business Overview
- 4.5.3 Pfizer Herceptin (Trastuzumab) Sales, Revenue and Gross Margin (2021-2026)
- 4.5.4 Pfizer Herceptin (Trastuzumab) Product Portfolio
- 4.5.5 Pfizer Recent Developments
- 4.6 Amgen
- 4.6.1 Amgen Company Information
- 4.6.2 Amgen Business Overview
- 4.6.3 Amgen Herceptin (Trastuzumab) Sales, Revenue and Gross Margin (2021-2026)
- 4.6.4 Amgen Herceptin (Trastuzumab) Product Portfolio
- 4.6.5 Amgen Recent Developments
- 4.7 Samsung Bioepis
- 4.7.1 Samsung Bioepis Company Information
- 4.7.2 Samsung Bioepis Business Overview
- 4.7.3 Samsung Bioepis Herceptin (Trastuzumab) Sales, Revenue and Gross Margin (2021-2026)
- 4.7.4 Samsung Bioepis Herceptin (Trastuzumab) Product Portfolio
- 4.7.5 Samsung Bioepis Recent Developments
- 4.8 Roche Diagnostics
- 4.8.1 Roche Diagnostics Company Information
- 4.8.2 Roche Diagnostics Business Overview
- 4.8.3 Roche Diagnostics Herceptin (Trastuzumab) Sales, Revenue and Gross Margin (2021-2026)
- 4.8.4 Roche Diagnostics Herceptin (Trastuzumab) Product Portfolio
- 4.8.5 Roche Diagnostics Recent Developments
- 4.9 Mundipharma
- 4.9.1 Mundipharma Company Information
- 4.9.2 Mundipharma Business Overview
- 4.9.3 Mundipharma Herceptin (Trastuzumab) Sales, Revenue and Gross Margin (2021-2026)
- 4.9.4 Mundipharma Herceptin (Trastuzumab) Product Portfolio
- 4.9.5 Mundipharma Recent Developments
- 4.10 Mabion
- 4.10.1 Mabion Company Information
- 4.10.2 Mabion Business Overview
- 4.10.3 Mabion Herceptin (Trastuzumab) Sales, Revenue and Gross Margin (2021-2026)
- 4.10.4 Mabion Herceptin (Trastuzumab) Product Portfolio
- 4.10.5 Mabion Recent Developments
- 4.11 InvivoGen
- 4.11.1 InvivoGen Company Information
- 4.11.2 InvivoGen Business Overview
- 4.11.3 InvivoGen Herceptin (Trastuzumab) Sales, Revenue and Gross Margin (2021-2026)
- 4.11.4 InvivoGen Herceptin (Trastuzumab) Product Portfolio
- 4.11.5 InvivoGen Recent Developments
- 4.12 Genentech
- 4.12.1 Genentech Company Information
- 4.12.2 Genentech Business Overview
- 4.12.3 Genentech Herceptin (Trastuzumab) Sales, Revenue and Gross Margin (2021-2026)
- 4.12.4 Genentech Herceptin (Trastuzumab) Product Portfolio
- 4.12.5 Genentech Recent Developments
- 4.13 Celltrion
- 4.13.1 Celltrion Company Information
- 4.13.2 Celltrion Business Overview
- 4.13.3 Celltrion Herceptin (Trastuzumab) Sales, Revenue and Gross Margin (2021-2026)
- 4.13.4 Celltrion Herceptin (Trastuzumab) Product Portfolio
- 4.13.5 Celltrion Recent Developments
- 4.14 Bio-Techne
- 4.14.1 Bio-Techne Company Information
- 4.14.2 Bio-Techne Business Overview
- 4.14.3 Bio-Techne Herceptin (Trastuzumab) Sales, Revenue and Gross Margin (2021-2026)
- 4.14.4 Bio-Techne Herceptin (Trastuzumab) Product Portfolio
- 4.14.5 Bio-Techne Recent Developments
- 4.15 Biocon Limited
- 4.15.1 Biocon Limited Company Information
- 4.15.2 Biocon Limited Business Overview
- 4.15.3 Biocon Limited Herceptin (Trastuzumab) Sales, Revenue and Gross Margin (2021-2026)
- 4.15.4 Biocon Limited Herceptin (Trastuzumab) Product Portfolio
- 4.15.5 Biocon Limited Recent Developments
- 4.16 AryoGen Biopharma
- 4.16.1 AryoGen Biopharma Company Information
- 4.16.2 AryoGen Biopharma Business Overview
- 4.16.3 AryoGen Biopharma Herceptin (Trastuzumab) Sales, Revenue and Gross Margin (2021-2026)
- 4.16.4 AryoGen Biopharma Herceptin (Trastuzumab) Product Portfolio
- 4.16.5 AryoGen Biopharma Recent Developments
- 4.17 Abnova Corporation
- 4.17.1 Abnova Corporation Company Information
- 4.17.2 Abnova Corporation Business Overview
- 4.17.3 Abnova Corporation Herceptin (Trastuzumab) Sales, Revenue and Gross Margin (2021-2026)
- 4.17.4 Abnova Corporation Herceptin (Trastuzumab) Product Portfolio
- 4.17.5 Abnova Corporation Recent Developments
5 Global Herceptin (Trastuzumab) Market Scenario by Region
- 5.1 Global Herceptin (Trastuzumab) Market Size by Region: 2021 VS 2025 VS 2032
- 5.2 Global Herceptin (Trastuzumab) Sales by Region: 2021-2032
- 5.2.1 Global Herceptin (Trastuzumab) Sales by Region: 2021-2026
- 5.2.2 Global Herceptin (Trastuzumab) Sales by Region: 2027-2032
- 5.3 Global Herceptin (Trastuzumab) Revenue by Region: 2021-2032
- 5.3.1 Global Herceptin (Trastuzumab) Revenue by Region: 2021-2026
- 5.3.2 Global Herceptin (Trastuzumab) Revenue by Region: 2027-2032
- 5.4 North America Herceptin (Trastuzumab) Market Facts & Figures by Country
- 5.4.1 North America Herceptin (Trastuzumab) Market Size by Country: 2021 VS 2025 VS 2032
- 5.4.2 North America Herceptin (Trastuzumab) Sales by Country (2021-2032)
- 5.4.3 North America Herceptin (Trastuzumab) Revenue by Country (2021-2032)
- 5.4.4 United States
- 5.4.5 Canada
- 5.5 Europe Herceptin (Trastuzumab) Market Facts & Figures by Country
- 5.5.1 Europe Herceptin (Trastuzumab) Market Size by Country: 2021 VS 2025 VS 2032
- 5.5.2 Europe Herceptin (Trastuzumab) Sales by Country (2021-2032)
- 5.5.3 Europe Herceptin (Trastuzumab) Revenue by Country (2021-2032)
- 5.5.4 Germany
- 5.5.5 France
- 5.5.6 U.K.
- 5.5.7 Italy
- 5.5.8 Netherlands
- 5.6 Asia Pacific Herceptin (Trastuzumab) Market Facts & Figures by Country
- 5.6.1 Asia Pacific Herceptin (Trastuzumab) Market Size by Country: 2021 VS 2025 VS 2032
- 5.6.2 Asia Pacific Herceptin (Trastuzumab) Sales by Country (2021-2032)
- 5.6.3 Asia Pacific Herceptin (Trastuzumab) Revenue by Country (2021-2032)
- 5.6.4 China
- 5.6.5 Japan
- 5.6.6 South Korea
- 5.6.7 India
- 5.6.8 Australia
- 5.6.9 China Taiwan
- 5.6.10 Southeast Asia
- 5.7 South America Herceptin (Trastuzumab) Market Facts & Figures by Country
- 5.7.1 South America Herceptin (Trastuzumab) Market Size by Country: 2021 VS 2025 VS 2032
- 5.7.2 South America Herceptin (Trastuzumab) Sales by Country (2021-2032)
- 5.7.3 South America Herceptin (Trastuzumab) Revenue by Country (2021-2032)
- 5.7.4 Mexico
- 5.7.5 Brazil
- 5.7.6 Argentina
- 5.8 Middle East and Africa Herceptin (Trastuzumab) Market Facts & Figures by Country
- 5.8.1 Middle East and Africa Herceptin (Trastuzumab) Market Size by Country: 2021 VS 2025 VS 2032
- 5.8.2 Middle East and Africa Herceptin (Trastuzumab) Sales by Country (2021-2032)
- 5.8.3 Middle East and Africa Herceptin (Trastuzumab) Revenue by Country (2021-2032)
- 5.8.4 Turkey
- 5.8.5 Saudi Arabia
- 5.8.6 UAE
6 Segment by Type
- 6.1 Global Herceptin (Trastuzumab) Sales by Type (2021-2032)
- 6.1.1 Global Herceptin (Trastuzumab) Sales by Type (2021-2032) & (K Units)
- 6.1.2 Global Herceptin (Trastuzumab) Sales Market Share by Type (2021-2032)
- 6.2 Global Herceptin (Trastuzumab) Revenue by Type (2021-2032)
- 6.2.1 Global Herceptin (Trastuzumab) Sales by Type (2021-2032) & (US$ Million)
- 6.2.2 Global Herceptin (Trastuzumab) Revenue Market Share by Type (2021-2032)
- 6.3 Global Herceptin (Trastuzumab) Price by Type (2021-2032)
7 Segment by Application
- 7.1 Global Herceptin (Trastuzumab) Sales by Application (2021-2032)
- 7.1.1 Global Herceptin (Trastuzumab) Sales by Application (2021-2032) & (K Units)
- 7.1.2 Global Herceptin (Trastuzumab) Sales Market Share by Application (2021-2032)
- 7.2 Global Herceptin (Trastuzumab) Revenue by Application (2021-2032)
- 7.2.1 Global Herceptin (Trastuzumab) Sales by Application (2021-2032) & (US$ Million)
- 7.2.2 Global Herceptin (Trastuzumab) Revenue Market Share by Application (2021-2032)
- 7.3 Global Herceptin (Trastuzumab) Price by Application (2021-2032)
8 Value Chain and Sales Channels Analysis of the Market
- 8.1 Herceptin (Trastuzumab) Value Chain Analysis
- 8.1.1 Herceptin (Trastuzumab) Key Raw Materials
- 8.1.2 Raw Materials Key Suppliers
- 8.1.3 Herceptin (Trastuzumab) Production Mode & Process
- 8.2 Herceptin (Trastuzumab) Sales Channels Analysis
- 8.2.1 Direct Comparison with Distribution Share
- 8.2.2 Herceptin (Trastuzumab) Distributors
- 8.2.3 Herceptin (Trastuzumab) Customers
9 Global Herceptin (Trastuzumab) Analyzing Market Dynamics
- 9.1 Herceptin (Trastuzumab) Industry Trends
- 9.2 Herceptin (Trastuzumab) Industry Drivers
- 9.3 Herceptin (Trastuzumab) Industry Opportunities and Challenges
- 9.4 Herceptin (Trastuzumab) Industry Restraints
10 Report Conclusion
11 Disclaimer
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst